Association of serum cystatin C levels with acute coronary syndrome in patients of advanced age

Qingyu Huang*, Wei Shen*, Jian Li, Xinping Luo, Haiming Shi, Pingping Yan and Jinjin Zhang

Abstract
Objective: This study was performed to investigate the relationship between the serum cystatin C (Cys C) level and acute coronary syndrome (ACS) in patients of advanced age.
Methods: The study included 184 patients with ACS and 46 healthy control subjects. Statistical analysis was performed using SPSS version 14.0 (SPSS Inc., Chicago, IL, USA).
Results: The serum Cys C level was significantly higher in patients with than without ACS (1.24 ± 0.30 vs. 1.42 ± 0.46 mg/L, respectively). Patients with more stenotic coronary arteries were significantly more likely to have higher median serum Cys C and creatinine levels and a lower estimated glomerular filtration rate. The multivariate logistic regression analysis demonstrated that the serum Cys C level was independently associated with the presence of ACS and the quantity of stenotic coronary arteries after adjustment for confounding factors. Additionally, the serum Cys C level was positively correlated with age, the creatinine level, and the N-terminal pro-B-type natriuretic peptide level in all patients but was negatively correlated with the estimated glomerular filtration rate.
Conclusion: A high serum Cys C level was independently associated with ACS and the quantity of stenotic coronary arteries in patients of advanced age regardless of renal function.

Keywords
Acute coronary syndrome, serum cystatin C, advanced age, stenosis, estimated glomerular filtration rate, creatinine, N-terminal pro-B-type natriuretic peptide

Date received: 8 October 2018; accepted: 4 February 2019

*These authors contributed equally to this work.

Corresponding author:
Jinjin Zhang, Department of Cardiology, Huashan Hospital, Fudan University, 12th Wulumuqi Road, Shanghai 200040, People’s Republic of China.
Email: m17721356976@163.com
**Introduction**

Acute coronary syndrome (ACS), including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction, is a leading cause of death and disability worldwide.\(^1\) Patients of advanced age constitute a large proportion of patients presenting with ACS.\(^2\) In the United States, the median age at ACS presentation is 68 years (interquartile range, 56–79 years).\(^3\) As the population grows older, especially in developing countries, increasing numbers of advanced-age patients present with ACS. However, patients of advanced age with ACS are more likely to have more comorbidities including chronic heart failure, arrhythmia, diabetes, cerebrovascular disease, chronic respiratory disease, and renal insufficiency.\(^2\)

The typical symptoms of angina are not always observed in patients with such conditions; additionally, the diagnostic specificity of cardiac troponins may be decreased. Therefore, early diagnosis and evaluation of the severity of ACS is sometimes difficult in older patients.

Cystatin C (Cys C) is a cysteine protease inhibitor produced by nearly all human cells and excreted into the bloodstream. With a low molecular weight of 13 kD, the protein is freely filtered by the renal glomerulus and then metabolized by the proximal tubule.\(^4\) Compared with creatinine, Cys C may have a particular advantage for diagnosis in patients of advanced age because its level in the blood does not seem to be influenced by age, sex, race, or muscle mass.\(^5,6\) The results of several cardiovascular health studies have demonstrated that Cys C has a much stronger and more linear association with the risk of mortality than does creatinine or creatinine-based estimates of the glomerular filtration rate (GFR).\(^4,6–8\) Moreover, some evidence has suggested that Cys C can be influenced by inflammation and may be intricately involved in the pathogenesis of atherosclerosis.\(^9,10\) All of these properties may render Cys C a potential biomarker in the early diagnosis of ACS and evaluation of its severity in patients of advanced age.

However, few data exist on the relationship between the serum Cys C level and ACS in patients of advanced age with or without chronic renal insufficiency. This study was performed to examine whether the serum Cys C level is associated with ACS and the number of stenotic coronary arteries in patients of advanced age regardless of the presence of renal insufficiency.

**Methods**

**Patient population and study design**

Patients of advanced age with suspected ACS who underwent diagnostic coronary angiography at North Huashan Hospital of Fudan University from January 2016 to December 2017 were enrolled in this study. After coronary angiography, the patients were divided into two groups: those who had been diagnosed with ACS and those who had no coronary stenosis. To evaluate the severity of ACS, the patients were further divided into three subgroups according to the number of stenotic coronary arteries (the 1-, 2, and 3-vessel groups). We only enrolled patients aged >60 years. We collected blood samples from each patient and recorded their age, sex, medical history, number of stenotic coronary arteries, and other clinical information. The study was performed according to the guidelines of the declaration of Helsinki and was approved by the ethics committee of North Huashan Hospital of Fudan University. All patients participating in the study provided verbal informed consent.
**Definition of ACS**

All patients met the diagnostic criteria defined by 2014 American Heart Association/American College of Cardiology guideline for the management of patients with non-ST-segment elevation ACSs and the 2013 American College of Cardiology Foundation/American Heart Association guideline for the management of ST-segment elevation myocardial infarction.

**Inclusion and exclusion criteria**

The inclusion criteria were fulfillment of the above-mentioned diagnostic criteria, age of >60 years, and coronary artery stenosis of ≥50% in at least one main coronary artery as confirmed by coronary angiography. Patients both with and without renal insufficiency were enrolled. The exclusion criteria were comorbid diseases including cardiomyopathy, valvular heart disease, myocarditis, acute cerebrovascular accident, acute infection, and advanced cancer and/or a medical history of a previous myocardial infarction, coronary stenting, and/or coronary bypass surgery.

**Coronary angiography**

The patients were evaluated by coronary angiography, and coronary artery disease was defined as visual stenosis of ≥50% in at least one of the three major coronary arteries. The left anterior descending artery, left circumflex artery, and right coronary artery were examined to evaluate the number of stenotic coronary arteries and thus determine whether the patient had 0- to 3-vessel disease. Involvement of the left main trunk was evaluated as 2-vessel disease by itself. The coronary angiography results were independently evaluated by two expert investigators.

**Analysis of serum Cys C level**

The concentration of serum Cys C was measured using a kit provided by Kyokuto Pharmaceutical Industrial (Tokyo, Japan), and the level is expressed in units of mg/dL. The reference value of Cys C is ≤1.0 mg/L. In all patients, the serum Cys C concentration was measured within 24 h after admission.

**Other data collection**

The relevant data were collected from the patients’ medical records. The levels of N-terminal pro-B-type natriuretic peptide, serum creatinine, fasting blood glucose, and low-density lipoprotein cholesterol (LDL-C) were measured by clinically approved assays on the same platform. The estimated GFR (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation, which can be expressed as follows:

\[
\text{eGFR} = 135 \times \min(\frac{\text{Scr}}{\kappa}, 1)^{0.609} \times \max(\frac{\text{Scr}}{\kappa}, 1)^{-0.711} \times 0.995^{\text{age}} \times 0.969 \times (\text{if female}) \times 1.08 \times (\text{if black})
\]

where Scr is serum creatinine, Scys is serum cystatin C, \( \kappa \) is 0.7 for females and 0.9 for males, \( z \) is −0.248 for females and −0.207 for males, min indicates the minimum of Scr/\( \kappa \) or 1, and max indicates the maximum of Scr/\( \kappa \) or 1.

**Statistical analysis**

Continuous variables are expressed as mean ± standard error of the mean or median [interquartile range], and categorical data are summarized as proportion and frequency as appropriate. If the parameters followed a normal distribution, the t-test was used to compare the differences.
between two groups. One-way analysis of variance was used when there were more than two groups; otherwise, the Mann–Whitney U test and Kruskal–Wallis H test were used, respectively. The categorical variables were compared using the \( \chi^2 \) test or Fisher’s exact test. Factors considered to affect ACS and the number of stenotic coronary arteries were evaluated using a multivariate logistic regression model. Correlations between the serum Cys C level and creatinine level as well as other biochemical parameters (age, LDL-C concentration, and eGFR) were assessed with Pearson’s correlation analysis. All tests were two-sided. \( P \) values of \( \leq 0.05 \) were considered statistically significant. The statistical analysis was performed using SPSS version 14.0 (SPSS Inc., Chicago, IL, USA).

**Results**

**Patient characteristics**

All patient characteristics are shown in Table 1. In total, 230 patients who underwent coronary angiography were enrolled in the study. Among the 230 patients, 184 were diagnosed with ACS and 46 had no coronary stenosis. There were no significant differences in clinical features such as age, medical history, N-terminal pro-B-type natriuretic peptide level, and renal function as measured by the serum creatinine level and eGFR among the groups. The patients in both groups were of advanced age. Compared with the controls, the patients with ACS had a higher proportion of men (\( P = 0.032 \)) and a higher median LDL-C level (\( P = 0.02 \)). Moreover, the serum Cys C level was significantly higher in patients with than without ACS (1.42 ± 0.46 vs. 1.24 ± 0.30 mg/L, respectively; \( P = 0.015 \)) (Figure 1).

To further analyze the severity of ACS, the 184 patients with ACS were divided into 3 subgroups (1-, 2-, and 3-vessel disease) according to the number of stenotic coronary arteries. As demonstrated in Table 2, significant differences were found in the serum Cys C concentration, creatinine

| Characteristic          | non-ACS  | ACS     | \( P \)-value |
|-------------------------|---------|---------|--------------|
|                         | n = 46  | n = 184 |              |
| Age, years              | 72.6 (67.75–78.25) | 72.8 (66–79) | 0.968 |
| Sex, male               | 21 (45.7) | 116 (63.0) | 0.032 |
| History of CHF          | 4 (8.7)  | 26 (14.1) | 0.463 |
| History of HBP          | 31 (67.4) | 131 (71.2) | 0.613 |
| History of DM           | 8 (17.4) | 57 (31.0) | 0.067 |
| LDL-C, mg/dL            | 2.38 ± 0.72 | 2.72 ± 0.92 | 0.02 |
| Cystatin C, mg/L        | 1.24 ± 0.30 | 1.42 ± 0.46 | 0.015 |
| Creatinine, μmol/L      | 79.52 ± 20.45 | 83.82 ± 24.78 | 0.278 |
| eGFR, mg/mL/1.73 m²     | 65.11 ± 14.73 | 60.75 ± 16.72 | 0.107 |
| NT-proBNP, pg/mL        | 523.47 ± 494.94 | 827.10 ± 1140.24 | 0.064 |
| Angiography             | –        | 101 (54.9) | – |
| 1-vessel disease        | –        | 69 (37.5) | – |
| 2-vessel disease        | –        | 14 (7.6)  | – |

Data presented as mean ± standard deviation, median (interquartile range), or n (%). ACS, acute coronary syndrome; CHF, chronic heart failure; HBP, high blood pressure; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
concentration, and eGFR among these groups. Patients with more stenotic coronary arteries were likely to have a higher median serum Cys C concentration (P = 0.001) (Figure 2) and creatinine concentration (P < 0.001) and a lower eGFR (P < 0.001). No significant differences existed in other clinical parameters.

**Figure 1.** Differences in serum Cys C level between participants with and without ACS. Cys C, cystatin C; ACS, acute coronary syndrome.

**Table 2.** Baseline clinical characteristics of participants according to the quantity of stenotic coronary arteries.

| Characteristic       | non-ACS (n = 46) | 1 vessel (n = 101) | 2 vessels (n = 69) | 3 vessels (n = 14) | P-value |
|----------------------|------------------|-------------------|-------------------|-------------------|---------|
| Age, years, years    | 72.60 ± 6.30     | 71.54 ± 7.34      | 74.09 ± 7.62      | 75.00 ± 8.75      | 0.098   |
| Sex, male            | 21 (45.7)        | 67 (66.3)         | 40 (58.0)         | 9 (64.3)          | 0.121   |
| History of CHF       | 4 (8.7)          | 11 (10.9)         | 12 (17.4)         | 3 (21.4)          | 0.319   |
| History of HBP       | 31 (67.4)        | 69 (68.3)         | 51 (73.9)         | 11 (78.6)         | 0.767   |
| History of DM        | 8 (17.4)         | 26 (25.7)         | 24 (34.8)         | 7 (50.0)          | 0.052   |
| LDL-C, mg/dL         | 2.38 ± 0.72      | 2.70 ± 0.93       | 2.74 ± 0.82       | 2.77 ± 1.29       | 0.133   |
| Cystatin C, mg/L     | 1.24 ± 0.30      | 1.28 ± 0.30       | 1.50 ± 0.40       | 2.04 ± 1.00       | <0.001  |
| Creatinine, µmol/L   | 79.52 ± 20.45    | 78.29 ± 20.57     | 87.64 ± 25.75     | 104.93 ± 33.60    | <0.001  |
| eGFR, mg/mL/1.73 m²  | 65.11 ± 14.73    | 66.52 ± 15.39     | 55.45 ± 14.40     | 45.25 ± 18.00     | <0.001  |
| NT-proBNP, pg/mL     | 523.47 ± 494.94  | 704.20 ± 927.55   | 933.55 ± 1374.83  | 1189.10 ± 1215.89 | 0.076   |

Data presented as mean ± standard deviation or n (%). ACS, acute coronary syndrome; CHF, chronic heart failure; HBP, high blood pressure; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Multiple logistic regression analysis

We conducted a multivariate logistic regression analysis to evaluate the potential predictors of ACS in the entire study population. As shown in Table 3, the multivariate logistic regression analysis revealed that the serum Cys C concentration was independently associated with ACS after adjustment for confounding factors (odds ratio [OR], 4.016; 95% confidence interval [CI], 1.242–12.986; \(P = 0.02\)).

We further evaluated the potential predictors of the severity of ACS using multivariate logistic regression analysis. As shown in Table 4, the multivariate

### Table 3. Multivariate logistic regression analysis model for prediction of ACS.

| Variables        | Odds ratio | 95% CI     | \(P\) |
|------------------|------------|------------|-------|
| Sex              | 2.006      | 1.012–3.973| 0.046 |
| History of DM    | 2.536      | 1.074–5.988| 0.034 |
| LDL-C            | 1.706      | 1.117–2.605| 0.013 |
| Cystatin C       | 4.016      | 1.242–12.986| 0.02  |

ACS, acute coronary syndrome; CI, confidence interval; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol.

### Table 4. Multivariate logistic regression analysis model for prediction of the quantity of stenotic coronary arteries.

| Variables        | Odds ratio | 95% CI     | \(P\) |
|------------------|------------|------------|-------|
| Age              | 0.999      | 0.958–1.043| 0.986 |
| Sex              | 0.674      | 0.342–1.328| 0.255 |
| History of CHF   | 0.708      | 0.318–1.571| 0.395 |
| History of HBP   | 1.063      | 0.607–1.861| 0.832 |
| History of DM    | 0.453      | 0.257–0.799| 0.006 |
| LDL-C            | 1.342      | 0.997–1.806| 0.052 |
| Cystatin C       | 5.646      | 1.250–25.508| 0.024 |
| Creatinine       | 0.990      | 0.969–1.010| 0.314 |
| eGFR             | 0.984      | 0.938–1.033| 0.513 |
| NT-proBNP        | 1.000      | 0.999–1.001| 0.091 |

CI, confidence interval; CHF, chronic heart failure; HBP, high blood pressure; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
logistic regression analysis revealed that the serum Cys C concentration was independently associated with the number of stenotic coronary arteries after adjustment for confounding factors (age, sex, medical history, LDL-C concentration, creatinine concentration, and eGFR) (OR, 5.646; 95% CI, 1.250–25.508; \( P = 0.024 \)).

Correlation analysis

As illustrated in Table 5 and Figure 3, the serum Cys C level was positively correlated with age and creatinine in all patients (\( r = 0.294, P < 0.001 \) and \( r = 0.626, P < 0.001 \), respectively), while it was negatively correlated with the eGFR (\( r = -0.830, P < 0.001 \)).

| Parameter             | \( r \)   | \( P \)       |
|-----------------------|-----------|---------------|
| Age, years            | 0.294     | <0.001        |
| LDL-C, mg/dL          | 0.121     | 0.068         |
| Creatinine, µmol/L    | 0.626     | <0.001        |
| eGFR, mL/min/1.73 m²  | -0.830    | <0.001        |
| NT-proBNP, pg/mL      | 0.159     | 0.016         |

Table 5. Correlations between serum cystatin C level and other parameters.

LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-B-type natriuretic peptide

Discussion

In the present study, the serum Cys C level was significantly higher in advanced-age patients with ACS regardless of renal function. Furthermore, the number of stenotic coronary arteries was associated with the expression level of Cys C in serum. Moreover, the multivariate logistic regression analysis indicated that an increased serum Cys C concentration could be an independent variable for ACS and the number of stenotic coronary arteries after adjustment. The data also showed that the serum Cys C concentration was significantly and positively correlated with the creatinine level but negatively correlated with the eGFR. Thus, measurement of the serum Cys C level could be useful for identifying individuals at risk of ACS and predicting the severity of ACS in patients of advanced age.

ACS is the leading cause of death and disability worldwide, and its prevalence increases with age.\(^{1,15}\) ACS is induced by the rupture of an atherosclerotic plaque and subsequent luminal thrombosis.\(^{16}\) The diagnostic approach to suspected ACS includes three major components: assessment of the clinical profile or symptoms, electrocardiographic examination, and measurement of cardiac biomarkers (especially troponins). However, these three evaluations can be difficult to perform in patients of advanced age, hindering the timely diagnosis of ACS. Cardiac troponins are significantly more often elevated in older patients in the absence of ACS because of impaired renal function, arrhythmias, and diastolic and/or systolic heart failure. Therefore, exploring a new potential biomarker to assist in the diagnosis of ACS in patients of advanced age is very important.

Cys C is an endogenous cysteine proteinase inhibitor produced by nucleated cells. Under conditions of ischemia and hypoxia, cardiomyocytes produce Cys C and release it into the blood.\(^{17}\) Studies have demonstrated that a high Cys C concentration is directly related to both inflammation and atherosclerosis.\(^{18}\) Therefore, this marker could be associated with the development and progression of atheroma plaques.\(^{19}\) Because of its low molecular weight, Cys C is freely filtrated by the glomeruli and reabsorbed by the renal tubules and less strongly influenced by sex, age, and muscle mass. Therefore, Cys C has been proposed as an early and sensible marker of glomerular function and a better marker for detection of mild renal impairment.\(^{20}\) Previous clinical studies have
confirmed that Cys C is a predictor of cardiovascular events in patients with impaired renal function. In the current study, we assessed the association between Cys C and ACS in patients of advanced age regardless of their kidney function to avoid the well-known effect of overt renal insufficiency on coronary artery disease. Our study demonstrated that the serum level of Cys C, but not the serum creatinine level or eGFR, was

Figure 3. (a) Correlation between serum levels of Cys C and creatinine. (b) Correlation between serum Cys C level and eGFR. Cys C, cystatin C; eGFR, estimated glomerular filtration rate.
independently associated with the presence of ACS, although the serum Cys C level was positively correlated with the creatinine level and negatively correlated with the eGFR.

In part, the results of this study are consistent with some previous studies that demonstrated that a high Cys C level is a risk factor for ACS (OR, 1.002; 95% CI, 1.00029–1.004; *P* = 0.02) and ST-segment elevated myocardial infarction (OR, 1.0009; 95% CI, 0.99–1.002; *P* = 0.04) and that it could play an important role in the early diagnosis and prevention of adverse cardiovascular events. Similar observations were made by Alhusseiny et al., who found that the serum Cys C level in patients with AMI was significantly increased at the time of admission (1296.0 ± 431.8 ng/mL) and discharge (1244.6 ± 482 ng/mL) compared with the reference level in healthy subjects (0.7 ± 0.2 ng/mL). Lodh et al. also found that the serum Cys C level was significantly higher in patients with ACS than in healthy controls. However, few studies have focused on patients of advanced age with ACS. The mean age of the patients with ACS in the present study was 72.8 years (interquartile range, 66–79 years). This mean age is higher than that in previously published research. In addition, when the association between the Cys C level and severity of ACS was evaluated, we found a positive relationship between the serum cystatin C level and the number of diseased vessels.

The present study has several limitations. First, the findings of this study only suggest an association between the serum Cys C level and ACS. Because of the limited sample sizes in the subgroups, we did not further explore the relationships between the serum Cys C level and the types of ACS (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevated myocardial infarction).

Second, angiographic information was limited to the number of stenotic coronary arteries. To ensure consistence with clinical practice worldwide, experienced angiographers assessed coronary stenosis by visual estimation rather than by quantitative evaluation. Third, this was a single-center study with a relatively small number of patients. The sample size should be increased to enhance the power of the statistical analysis. Thus, further studies with a larger sample size are needed to confirm the results and to validate the clinical implication of serum Cys C as a diagnostic biomarker of ACS.

Conclusions

In conclusion, our findings demonstrate that a high serum Cys C level is independently associated with ACS and the quantity of stenotic coronary arteries in patients of advanced age regardless of renal function. Thus, serum Cys C may be a potential biomarker of ACS. Measurement of the serum Cys C level might be useful for identifying individuals at risk of ACS and predicting the quantity of stenotic coronary arteries in patients of advanced age.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Jinjin Zhang  http://orcid.org/0000-0002-0557-3268
References
1. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics–2014 update: a report from the American Heart Association. *Circulation* 2014; 129: 399–410.
2. Savonitto S, Morici N and De Servi S. Update: acute coronary syndromes (VI): treatment of acute coronary syndromes in the elderly and in patients with comorbidities. *Rev Esp Cardiol (Engl Ed)* 2014; 67: 564–573.
3. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014; 64: e139–e228.
4. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. *N Engl J Med* 2005; 352: 2049–2060.
5. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. *Am J Kidney Dis* 2000; 36: 29–34.
6. Shlipak MG, Katz R, Fried LF, et al. Cystatin-C and mortality in elderly persons with heart failure. *J Am Coll Cardiol* 2005; 45: 268–271.
7. Lassus J, Harjola VP, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. *Eur Heart J* 2007; 28: 1841–1847.
8. Ix JH, Shlipak MG, Chertow GM, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. *Circulation* 2007; 115: 173–179.
9. Maahs DM, Ogden LG, Kretowski A, et al. Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. *Diabetes* 2007; 56: 2774–2779.
10. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. *Kidney Int* 2004; 65: 1416–1421.
11. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013; 127: e362–e425.
12. Wang GN, Sun K, Hu DL, et al. Serum cystatin C levels are associated with coronary artery disease and its severity. *Clin Biochem* 2014; 47: 176–181.
13. Zhang J, Wu X, Gao P, et al. Correlations of serum cystatin C and glomerular filtration rate with vascular lesions and severity in acute coronary syndrome. *BMC Cardiovasc Disord* 2017; 17: 47.
14. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med* 2012; 367: 20–29.
15. Nichols M, Townsend N, Scarborough P, et al. Cardiovascular disease in Europe: epidemiological update. *Eur Heart J* 2013; 34: 3028–3034.
16. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler Thromb Vasc Biol* 2000; 20: 1262–1275.
17. Abid L, Charfeddine S, Kammoun S, et al. Cystatin C: a prognostic marker after myocardial infarction in patients without chronic kidney disease. *J Saudi Heart Assoc* 2016; 28: 144–151.
18. Tagliero N, Koenig W and Kaski JC. Cystatin C and cardiovascular risk. *Clin Chem* 2009; 55: 1932–1943.
19. Ge C, Ren F, Lu S, et al. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. *Clin Cardiol* 2009; 32: 644–648.
20. Hamzic-Mehmedbasic A. Inflammatory cytokines as risk factors for mortality after acute cardiac events. *Med Arch* 2016; 70: 252–255.
21. Gibson CM, Dumaine RL, Gelfand EV, et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. *Eur Heart J* 2004; 25: 1998–2005.

22. Pitsavos C, Kourlaba G, Panagiotakos DB, et al. Association of creatinine clearance and in-hospital mortality in patients with acute coronary syndromes: the GREECS study. *Circ J* 2007, 71: 9–14.

23. Schiele F, Legalery P, Didier K, et al. Impact of renal dysfunction on 1-year mortality after acute myocardial infarction. *Am Heart J* 2006; 151: 661–667.

24. Negrusz-Kawecka M, Porgba R, Hulok A, et al. Evaluation of the significance of cystatin C levels in patients suffering from coronary artery disease. *Adv Clin Exp Med* 2014; 23: 551–558.

25. Alhusseiny AH, Al-Nimer MS and Al-Neamy SI. Assessment of serum cystatin c levels in newly diagnosed acute myocardial infarction at the onset and at the time of hospital discharge. *Cardiol Res* 2015; 6: 226–231.

26. Lodh M, Parida A, Sanyal J, et al. Cystatin C in acute coronary syndrome. *EJIFCC* 2013; 24: 61–67.